Michael A. Mussallem has been chairman and chief executive officer since 2000 when the company spun-off from Baxter International. Prior to his current position, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter, including group vice president of its cardiovascular business from 1994 to 2000 and group vice president of the biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the chairman of Baxter's Asia board overseeing Baxter's operations throughout Asia. Mussallem is the former chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed). He is currently on the boards and executive committees of AdvaMed, California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. Mussallem received a bachelor’s degree in chemical engineering and an honorary doctorate degree from the Rose-Hulman Institute of Technology in Terre Haute, Indiana.

Donald E. Bobo, Jr. has been corporate vice president, heart valve therapy since 2007 and is responsible for the company’s surgical heart valve business, including tissue replacement and repair devices. Bobo has over 25 years of experience in the medical products and healthcare industry where he most recently served as Edwards’ vice president and general manager of transcatheter mitral repair and as vice president, corporate strategy. Prior to joining Edwards, he served as director and general manager of the non-invasive monitoring business unit of InnerSpace, a medical device startup company. Since 2004, Bobo has served on the school of biological sciences Dean’s Leadership Council at the University of California, Irvine. From 2001 to 2006, he served as a director and board member of PLC Medical. He received his bachelor's degree in mathematics from Bob Jones University and a master's degree in engineering from the University of Southern California.

John H. Kehl, Jr. has been corporate vice president, strategy and corporate development since 2000. Previously, he held various positions of increasing responsibility at Baxter International since joining its treasury department in 1975, including investor relations, communications, controller for Baxter’s cardiovascular business and business development. Kehl also served on Baxter’s Japan board. He received his bachelor’s degree in business and economics from Loras College and his master’s degree in business administration from Loyola University in Chicago.

Christine Z. McCauley has been corporate vice president, human resources since August 2012. McCauley has more than 25 years of experience working in all the functional disciplines of human resources. Prior to assuming her current role, she served Edwards as vice president, human resources. Before joining the company in 1999, McCauley held a variety of human resources positions at Texas Instruments, Loral (Ford) Aerospace and Bally’s Health and Tennis. She is a member of the advisory board of Healthcare Businesswomen's Association Southern California Chapter. McCauley earned a dual bachelor’s degree in business administration and organizational effectiveness at The College at Brockport State University of New York and her master’s degree in human resource management from Chapman University.

Carlyn D. Solomon has been corporate vice president, critical care since 2007 and is responsible for Edwards’ global market-leading critical care and vascular businesses, as well as corporate quality and regulatory affairs. Solomon has more than 25 years of leadership experience in the medical device, biotechnology and pharmaceutical industries. Prior to joining Edwards in 2005, he served in a number of positions with increasing responsibility at Baxter International, including interim president of the company’s bioscience division, vice president of global manufacturing, and vice president of global operations. During his tenure at Baxter, the organization received numerous awards for manufacturing and operational excellence, and was instrumental in developing revolutionary technologies. Solomon has served as an executive board member for the California Manufacturers and Technology Association and the Plasma Protein Therapeutics Association. He also served on the board of directors for The Baxter International Foundation. Solomon earned a bachelor’s degree in industrial engineering from Kansas State University.

Huimin Wang, M.D. is corporate vice president, Japan and Asia Pacific. Prior to his current role, Wang was responsible for the company’s Japan and Intercontinental regions. Since joining the company (then Baxter International) in 1993, Wang has served in a number of roles including senior manager of strategy development, director of product/therapy for Baxter’s renal division in Japan, president of medical systems and devices, responsible for both the cardiovascular and intravenous systems businesses in Japan, and representative director of Baxter Limited. Previously, Wang was a senior associate with Booz, Allen & Hamilton in Chicago, vice president of Integrated Strategies, a consulting and venture management firm he co-founded, and an associate with McKinsey & Company. Prior to that, Wang was a resident and staff physician in anesthesiology at Keio University Hospital in Tokyo. Wang is the former chairman and advisor of the American Medical Devices and Diagnostics Manufacturers’ Association and the former chairman of the Medical Devices and Diagnostics Subcommittee of the American Chamber of Commerce in Japan. Additionally, in 2006, Wang was appointed as visiting associate professor for Keio University's department of anesthesiology. Wang received his doctor of medicine degree from Kagoshima University in Japan, and his master’s degree in business administration from the University of Chicago.

Larry L. Wood has been corporate vice president, transcatheter heart valves since 2007. Wood is responsible for leading the company’s transcatheter heart valve program globally. The program, which Wood has led since it was a development project, is based on Edwards’ 50 years at the forefront of heart valve innovation. Under his leadership, the company is substantially investing in next-generation product development and scientifically rigorous clinical studies around the world. In addition, the program has also led in the development of a comprehensive training approach for multi-disciplinary heart teams on this new valve implantation procedure, and has made substantial investments in healthcare economics studies. Wood has more than 25 years of experience in the medical device industry at both Edwards and Baxter International. His career experience includes key responsibilities in manufacturing management, regulatory affairs and strategic and clinical marketing, primarily in the company’s leading surgical heart valve franchise. Wood received his master’s degree in business administration from Pepperdine University.

Thomas M. Abate has been corporate vice president, chief financial officer since 2006. He has also served as the company’s treasurer and, previously, as the company’s corporate controller. In addition, Abate played an instrumental role in the company's spin-off from Baxter International in 2000. He also operated as group controller for Baxter's cardiovascular group and worked in a global capacity as vice president of finance for Clintec International, a joint venture with Baxter and Nestle based in Lausanne, Switzerland. Abate received a bachelor's degree in accounting from the University of Illinois and a master’s degree in business administration from Northern Illinois University.

Bruce P. Garren has been corporate vice president, public affairs and special counsel since January 2011 and previously served as the company’s general counsel beginning in 2000. Garren is responsible for government affairs, global reimbursement, global communications, medical affairs and specific legal matters. Prior to joining the company, he was senior vice president, general counsel for Safeskin Corporation, a San Diego-based manufacturer of latex and synthetic gloves for the healthcare and scientific markets. Garren began his legal career as an associate at Arnold & Porter in Washington, D.C. He is on the Board of Directors of the Alliance for Aging Research and is active in the Advanced Medical Technology Association, both in Washington. Garren received his undergraduate degree from Antioch College and his law degree from Cornell Law School.

Rich Lunsford has been corporate vice president, cardiac surgery systems since January 2012 and previously served as vice president and general manager, cardiac surgery systems since joining the company in February 2011. Lunsford has more than 25 years of experience in the medical device industry, including extensive experience in global sales and marketing. Before joining Edwards, Lunsford was president and CEO of Anulex Technologies, a Minnesota-based manufacturer of technologies used during spinal surgery. He has also served as president/CEO of Acorn Cardiovascular, president of commercial operations at ev3 and has held leadership positions at Scimed Life Systems/Boston Scientific, Allergan Medical Optics and Spinetech. Lunsford has been a board member for Acorn Cardiovascular, Anulex Technologies, Endius, and Tutogen Medical. He received his bachelor’s degree in multinational business operations from Florida State University.

John P. McGrath, Ph.D. has been corporate vice president, quality since 2007. He has more than 25 years of medical device and combination product experience in quality, manufacturing and product development. Prior to joining Edwards, McGrath was vice president of quality at Cordis Corporation, where his quality assurance responsibilities included cardiovascular, endovascular and neurovascular businesses. Prior to that, he was director of quality at CR Bard’s USCI and electrophysiology divisions. He received a bachelor’s degree from Trinity College, Dublin, Ireland, a master’s degree in total quality management from Sheffield Hallam University, United Kingdom, and a doctorate degree in management from California Coast University.

Stanton J. Rowe has been chief scientific officer since 2008 and also serves as corporate vice president, advanced technology. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technology, of which he was president and CEO and helped to found in 1999. Previously, Rowe was corporate vice president of business development and strategic planning for Datascope and was vice president of business development for Johnson & Johnson’s interventional systems division (JJIS), responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research, and marketing groups. Rowe joined Cordis after having held several positions in product management for various medical device companies. He is on the board of directors of both Remon Medical Ltd. and Biomerix. Rowe received his bachelor’s degree from the University of Alabama.

Patrick B. Verguet has been corporate vice president, EMEA (Europe, Middle East and Africa) and Latin America since 2004. Prior to assuming his current role, Verguet served as vice president of sales and country management in Europe. Verguet has more than 20 years of medical device experience beginning with Travenol in France, and held several sales and marketing management positions within Baxter Europe. Over the years, he served the company as global business director for hemofiltration and business unit/country manager for operations in the United Kingdom, France, Switzerland, Belgium, Netherlands and Nordic countries. Verguet also served as general manager of Edwards’ research medical operations in Utah, and as vice president and general manager of Edwards’ cardiac surgery systems business at the company’s corporate headquarters in Irvine. Verguet holds a degree as a doctor in pharmacy from the University of Besançon.

Aimee S. Weisner has been corporate vice president, general counsel since January 2011. Prior to joining the company, Weisner was the executive vice president, administration and secretary at Advanced Medical Optics, Inc. (AMO) where she was responsible for legal, human resources, compliance and internal audit, and previously served as general counsel. Prior to that, Weisner served as vice president, assistant general counsel and assistant secretary at Allergan. She also practiced in the corporate and securities group at the law firm of O’Melveny & Myers LLP. Weisner received her juris doctor degree from Loyola Law School in Los Angeles and her bachelor’s degree in communications from California State University, Fullerton.